Researchers have utilized optical coherence elastography (OCE) to map the spatial and temporal changes in corneal ...
2d
Man who lost his sight in ‘complete blackout’ now styles celebrities after life-changing surgery
JJ Savani, 36, was forced to give up his NHS career after losing his sight but an anonymous donation helped him build a ...
Glaukos has the iDose TR, which moves it beyond surgical devices into sustained drug delivery. Read why I lean neutral on ...
LASIK can reduce dependence on glasses, but vision changes may occur months or years later. Refractive regression, dry eyes, ...
- Glaukos GKOS -- secures second J-code (J2789) for Epioxa, a corneal cross-linking therapy, effective July 1, 2026, expanding its Medicare billing capabilities beyond glaucoma surgeries.
Il Cross-Linking Plus combina tecniche per contrastare la progressione del cheratocono e migliorare la qualità visiva in ...
At month 3, the 149-eye trial found a 7.4 mmHg reduction with surgery alone; iDose had no serious corneal adverse events ...
- Glaukos GKOS -6.32% (GKOS) stock fell 6.32% on Oct 8, 2026, despite $0.45B in trading volume, its highest daily turnover. - ...
Arun C. Gulani, MD, introduces a keratoconus classification based on what prevents vision: visual, structural, or salvage.
Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while ...
Epioxa, an epithelium-on corneal cross-linking therapy for keratoconus, demonstrated positive outcomes in visual acuity, ...
Glaukos Corporation (NYSE: GKOS) announced results from a long-term Phase 3 extension study evaluating its Epioxa corneal cross-linking therapy for keratoconus, showing sustained efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results